Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.49 |
| ▸ | P2RY14 | Q15391 | 7/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.37 |
| ▸ | MIF | P14174 | 3/20 | 0.36 |
| ▸ | STS | P08842 | 2/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.35 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SNCA | P37840 | 1/20 | 0.34 |
| ▸ | OGT | O15294 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16419734 | 0.95 | CYP1B1 (0.47) | CYP1B1P2RY14OPRD1SIGMAR1EGLN1 | |
| SCHEMBL15036884 | 0.91 | KEAP1 (0.42) | CYP1B1P2RY14OPRD1SIGMAR1EGLN1 | |
| SCHEMBL16419738 | 0.87 | KEAP1 (0.41) | CYP1B1P2RY14OPRD1SIGMAR1EGLN1 | |
| SCHEMBL15036894 | 0.80 | CYP1B1 (0.58) | CYP1B1P2RY14OPRD1SIGMAR1MIF | |
| SCHEMBL15036871 | 0.76 | OGT (0.43) | P2RY14OPRD1SIGMAR1EGLN1MIF | |
| SCHEMBL15274989 | 0.75 | CYP1B1 (0.56) | CYP1B1P2RY14MIFSTSSTIM1 | |
| SCHEMBL15274988 | 0.75 | CYP1B1 (0.56) | CYP1B1P2RY14MIFSTSSTIM1 | |
| SCHEMBL15037015 | 0.75 | PRSS1 (0.42) | CYP1B1 | |
| SCHEMBL16419773 | 0.74 | L3MBTL1 (0.43) | — | |
| SCHEMBL15277742 | 0.72 | CYP1B1 (0.48) | CYP1B1P2RY14OPRD1SIGMAR1MIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9469616-B2 | Cyclic compounds and methods of making and using the same | CELLCEUTIX CORPORATION (US) | 2016-10-18 | — | — | US | disclosed |
| US-9469616-B2 | Cyclic compounds and methods of making and using the same | CELLCEUTIX CORPORATION (US) | 2016-10-18 | — | — | US | disclosed |
| US-20150031738-A1 | CYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | UNIVERSITY OF MASSACHUSETTS (US) | 2015-01-29 | — | — | US | disclosed |
| US-20150031738-A1 | CYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | UNIVERSITY OF MASSACHUSETTS (US) | 2015-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031738-A1 | CYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MUC1, TLR3, ALG1 | CYP1B1 4315/4885P2RY14 3443/4885OPRD1 2100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.